[go: up one dir, main page]

BR112017027841A2 - composto de fenil amino pirimidina ou polimorfo de sal do mesmo - Google Patents

composto de fenil amino pirimidina ou polimorfo de sal do mesmo

Info

Publication number
BR112017027841A2
BR112017027841A2 BR112017027841-3A BR112017027841A BR112017027841A2 BR 112017027841 A2 BR112017027841 A2 BR 112017027841A2 BR 112017027841 A BR112017027841 A BR 112017027841A BR 112017027841 A2 BR112017027841 A2 BR 112017027841A2
Authority
BR
Brazil
Prior art keywords
polymorph
same
salt
phenyl amino
amino pyrimidine
Prior art date
Application number
BR112017027841-3A
Other languages
English (en)
Chinese (zh)
Inventor
Lv Binhua
Li Chengwei
Xiao Dan
Original Assignee
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Zelgen Biopharmaceuticals Co., Ltd. filed Critical Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Publication of BR112017027841A2 publication Critical patent/BR112017027841A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção refere-se a um composto de fenilamino-pirimidina ou a um polimorfo de um seu sal, especificamente, a n- (cianometil) -4-(2-(4-(2', 2', 6', 6'-d4- morfolino) fenil) amino) pirimidin-4-il) benzamida, ou um sal farmaceuticamente aceitável do mesmo, ou um polimorfo de um solvato do mesmo, isto é, um composto mostrado na fórmula i ou um sal do mesmo, ou um polimorfo de um solvato do mesmo. o polimorfo é adequado para a preparação de uma composição farmacêutica para supressão de tirosina quinases não receptoras (tal como jak cinase)
BR112017027841-3A 2015-06-26 2016-06-24 composto de fenil amino pirimidina ou polimorfo de sal do mesmo BR112017027841A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510364281.3 2015-06-26
CN201510364281.3A CN106316964B (zh) 2015-06-26 2015-06-26 苯基氨基嘧啶化合物或其盐的多晶型物
PCT/CN2016/087092 WO2016206633A1 (zh) 2015-06-26 2016-06-24 苯基氨基嘧啶化合物或其盐的多晶型物

Publications (1)

Publication Number Publication Date
BR112017027841A2 true BR112017027841A2 (pt) 2018-09-04

Family

ID=57584693

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017027841-3A BR112017027841A2 (pt) 2015-06-26 2016-06-24 composto de fenil amino pirimidina ou polimorfo de sal do mesmo

Country Status (9)

Country Link
US (1) US10377725B2 (pt)
EP (2) EP4056559A1 (pt)
JP (1) JP7139116B2 (pt)
KR (2) KR20200039838A (pt)
CN (2) CN106316964B (pt)
BR (1) BR112017027841A2 (pt)
CA (1) CA2990747C (pt)
RU (1) RU2712226C2 (pt)
WO (1) WO2016206633A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117304179A (zh) * 2022-06-21 2023-12-29 苏州泽璟生物制药股份有限公司 杰克替尼二盐酸盐一水合物的制备工艺
WO2024134481A1 (en) 2022-12-21 2024-06-27 Glaxosmithkline Llc Combination therapy comprising jaktinib

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54533B1 (en) * 2007-03-12 2016-06-30 Ym Biosciences Australia Pty Ltd PHENYL AMINOPYRIMIDINE COMPOUNDS AND THEIR APPLICATIONS
WO2009029998A1 (en) * 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
CN104473933A (zh) * 2010-12-03 2015-04-01 Ym生物科学澳大利亚私人有限公司 Jak-2 介导的病症的治疗
ES2672468T3 (es) * 2013-01-09 2018-06-14 Concert Pharmaceuticals Inc. Momelotinib deuterado
CN103965114B (zh) * 2013-01-28 2016-01-06 苏州泽璟生物制药有限公司 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
JP2016537433A (ja) * 2013-11-26 2016-12-01 ギリアード サイエンシーズ， インコーポレイテッド 骨髄増殖性障害を処置するための治療
TW202134236A (zh) * 2014-06-12 2021-09-16 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺

Also Published As

Publication number Publication date
RU2018102761A3 (pt) 2019-08-01
EP3315493A1 (en) 2018-05-02
CN107709304B (zh) 2020-12-04
US10377725B2 (en) 2019-08-13
KR20200039838A (ko) 2020-04-16
JP7139116B2 (ja) 2022-09-20
CN106316964A (zh) 2017-01-11
EP3315493A4 (en) 2019-07-10
RU2018102761A (ru) 2019-08-01
US20180179169A1 (en) 2018-06-28
CA2990747C (en) 2021-01-05
CN106316964B (zh) 2019-06-25
WO2016206633A1 (zh) 2016-12-29
CN107709304A (zh) 2018-02-16
EP3315493B1 (en) 2022-06-01
EP4056559A1 (en) 2022-09-14
CA2990747A1 (en) 2016-12-29
JP2018518515A (ja) 2018-07-12
KR20180080711A (ko) 2018-07-12
RU2712226C2 (ru) 2020-01-27

Similar Documents

Publication Publication Date Title
PH12016500467B1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
EA201692356A1 (ru) Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
PE20180227A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2018015625A (es) Compuestos y composiciones para inhibir la actividad de shp2.
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
HRP20231048T1 (hr) Derivati bipirazola kao jak inhibitori
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
UA112317C2 (uk) Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину
BR112015029090A8 (pt) 3,4-dihidroisoquinolin- 2(1h)-ila, seus usos, composição farmacêuticas e sua forma cocristalina
NZ629037A (en) Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EA033530B1 (ru) Композиции 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4-метилциклогексиламино)пиримидин-5-карбоксамида
BR112019008415A2 (pt) composto de piridona e inibidor de c-met, composição farmacêutica e uso dos mesmos
NZ630251A (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
BR112013031121A2 (pt) composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento
BR112017027841A2 (pt) composto de fenil amino pirimidina ou polimorfo de sal do mesmo
BR112018013364A2 (pt) forma cristalina e composição farmacêutica
PH12017501832A1 (en) Stabilized pharmaceutical composition
BR112017021589A2 (pt) métodos para o tratamento de transtornos cardiovasculares
BR112014006927A2 (pt) derivados de metanossulfonamida substituídos com amina como ligantes de receptor vaniloide
BR112017012558A2 (pt) Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09R Decision of refusal: republication [chapter 9.2.3 patent gazette]

Free format text: REPUBLICACAO DO DESPACHO 9.2 (RPI 2733, 23/05/2023)

B12B Appeal against refusal [chapter 12.2 patent gazette]